The specter of generic rivalry has consistently loomed over copyright’s blockbuster drug, Viagra, sparking questions about the outlook of connected drug portfolios. While early years saw impressive returns, the exclusivity lapse has created the way for less expensive substitutes, likely diminishing profitability and creating a genuine hazard for